These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24937799)

  • 1. Posterolateral lumbar fusion using Escherichia coli-derived rhBMP-2/hydroxyapatite in the mini pig.
    Kong CB; Lee JH; Baek HR; Lee CK; Chang BS
    Spine J; 2014 Dec; 14(12):2959-67. PubMed ID: 24937799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of fusion rate induced by different dosages of Escherichia coli-derived recombinant human bone morphogenetic protein-2 using hydroxyapatite carrier.
    Lee JH; Yu CH; Yang JJ; Baek HR; Lee KM; Koo TY; Chang BS; Lee CK
    Spine J; 2012 Mar; 12(3):239-48. PubMed ID: 22341396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate.
    Boden SD; Martin GJ; Morone MA; Ugbo JL; Moskovitz PA
    Spine (Phila Pa 1976); 1999 Jun; 24(12):1179-85. PubMed ID: 10382242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial.
    Cho JH; Lee JH; Yeom JS; Chang BS; Yang JJ; Koo KH; Hwang CJ; Lee KB; Kim HJ; Lee CK; Kim H; Suk KS; Nam WD; Han J
    Spine J; 2017 Dec; 17(12):1866-1874. PubMed ID: 28652196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental spinal fusion using sintered bovine bone coated with type I collagen and recombinant human bone morphogenetic protein-2.
    Minamide A; Tamaki T; Kawakami M; Hashizume H; Yoshida M; Sakata R
    Spine (Phila Pa 1976); 1999 Sep; 24(18):1863-70; discussion 1871-2. PubMed ID: 10515009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in a mini-pig spinal anterior interbody fusion model.
    Hwang CJ; Lee JH; Baek HR; Chang BS; Lee CK
    Bone Joint J; 2013 Feb; 95-B(2):217-23. PubMed ID: 23365032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis.
    Lina IA; Puvanesarajah V; Liauw JA; Lo SF; Santiago-Dieppa DR; Hwang L; Mao A; Bydon A; Wolinsky JP; Sciubba DM; Gokaslan Z; Holmes C; Witham TF
    Spine (Phila Pa 1976); 2014 Mar; 39(5):347-55. PubMed ID: 24365898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic, biomechanical, and histological evaluation of rhBMP-2 in a 3-level intertransverse process spine fusion: an ovine study.
    Toth JM; Wang M; Lawson J; Badura JM; DuBose KB
    J Neurosurg Spine; 2016 Dec; 25(6):733-739. PubMed ID: 27367941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion.
    Akamaru T; Suh D; Boden SD; Kim HS; Minamide A; Louis-Ugbo J
    Spine (Phila Pa 1976); 2003 Mar; 28(5):429-34. PubMed ID: 12616152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of carriers of bone morphogenetic protein for spinal fusion.
    Minamide A; Kawakami M; Hashizume H; Sakata R; Tamaki T
    Spine (Phila Pa 1976); 2001 Apr; 26(8):933-9. PubMed ID: 11317116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2.
    Itoh H; Ebara S; Kamimura M; Tateiwa Y; Kinoshita T; Yuzawa Y; Takaoka K
    Spine (Phila Pa 1976); 1999 Jul; 24(14):1402-5. PubMed ID: 10423783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Healos/bone marrow to INFUSE(rhBMP-2/ACS) with a collagen-ceramic sponge bulking agent as graft substitutes for lumbar spine fusion.
    Kraiwattanapong C; Boden SD; Louis-Ugbo J; Attallah E; Barnes B; Hutton WC
    Spine (Phila Pa 1976); 2005 May; 30(9):1001-7; discussion 1007. PubMed ID: 15864149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate.
    Suh DY; Boden SD; Louis-Ugbo J; Mayr M; Murakami H; Kim HS; Minamide A; Hutton WC
    Spine (Phila Pa 1976); 2002 Feb; 27(4):353-60. PubMed ID: 11840099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-term and mid-term histologic events during single-level posterolateral intertransverse process fusion with rhBMP-2/collagen carrier and a ceramic bulking agent in a nonhuman primate model: implications for bone graft preparation.
    Khan SN; Toth JM; Gupta K; Glassman SD; Gupta MC
    J Spinal Disord Tech; 2014 Jun; 27(4):212-9. PubMed ID: 23073151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of bone morphogenetic protein and basic fibroblast growth factor on cultured mesenchymal stem cells for spine fusion.
    Minamide A; Yoshida M; Kawakami M; Okada M; Enyo Y; Hashizume H; Boden SD
    Spine (Phila Pa 1976); 2007 May; 32(10):1067-71. PubMed ID: 17471086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumbar spinal fusion with β-TCP granules and variable Escherichia coli-derived rhBMP-2 dose.
    Pelletier MH; Oliver RA; Christou C; Yu Y; Bertollo N; Irie H; Walsh WR
    Spine J; 2014 Aug; 14(8):1758-68. PubMed ID: 24486479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyapatite granule graft combined with recombinant human bone morphogenic protein-2 for solid lumbar fusion.
    Konishi S; Nakamura H; Seki M; Nagayama R; Yamano Y
    J Spinal Disord Tech; 2002 Jun; 15(3):237-44. PubMed ID: 12131427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
    Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
    Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.